Dendritic cell pharmaceutical preparations

Indications of Dendritic cell preparation

Autologous immune cell therapy

Including CIK, NK, DC, DC-CIK, TIL, gamma-delta T adoptive T cell infusion therapy.
Indications of

  • Hematological malignancies do not respond to standard treatment
  • The first to third stage solid tumors (solid tumor), ineffective after standard treatment
  • The forth stage solid tumors (solid tumor)

Dendritic cell pharmaceutical preparations

The immune cell therapy products (LiDCR series) & (LmDCV series) that Leopard Cell can provide:

LiDCR

LiDCR is an “autologous immature dendritic cell” derived from peripheral blood mononuclear cells. It is used in a combined course of radiation therapy. Cells are injected directly into solid tumors. The production of cell preparations, quality testing, and release The implementation process and technology are completely developed and established by Leopard Cell. LiDCR is currently the only domestic clinical trial that combines single focused radiotherapy with intratumoral injection of autologous dendritic cells.

LmDCV

LmDCV is derived from “autologous mature dendritic cells” differentiated from peripheral blood mononuclear cells. The molecular detection technology of Leopard Gene is used to search for immunomodulatory genes and establish mutation genes corresponding to each indication. Sequence, and then synthesize the relevant antigen protein, then co-culture with autologous mature dendritic cells, make a vaccine in vitro, and then return it to the patient for cell therapy.

Autologous immune cell therapy indications

Radiation tumor treatment use

  • The immature dendritic cells of LiDCR are derived from peripheral blood mononuclear cells of the patient’s own body. (Applying)
  • The immature dendritic cells of LiDCR-PBSC are derived from peripheral blood stem cells of healthy people. (In development)

Hematological tumor treatment use

  • The mature dendritic cell vaccine of LmDCV is derived from the peripheral blood mononuclear cells of the patient’s own body. (In development)
  • The mature dendritic cell vaccine of LmDCV-PBSC is derived from the patient’s own peripheral blood stem cells. (In development)

Advantages of cell therapy

Any treatment is not absolute, you can refer to the advantages and limitations of each treatment.

Surgical treatment Destroy local tumors without invasive methods Chemotherapy
Advantages Removal of local tumor directly Destroy local tumors without invasive methods Systemic treatment of cancer cells that have spread
Limitation Cancer cells have spread, or non-solid tumors (such as blood cancer) are not applicable Cancer cells have spread, or non-solid tumors (such as blood cancer) are not applicable Will also destroy healthy cells, such as bone marrow cells
Therapeutic range Locality Locality Systemic
Side effects The function may be affected by removing nerves or other normal tissues Fibrosis or necrosis of peripheral normal cells The side effects are serious, such as reduced immunity, hair loss, mouth and throat ulcers, nausea, vomiting, diarrhea, etc.
Immune checkpoint inhibitor Immune Cell Therapy
Advantage Under long-term control Suitable for all cancers and low side effects
Limitation The treatment response rate is low (20~30%), which may over-activate the immune system and induce autoimmune diseases Depends on the status of autoimmune cells
Therapeutic range Systemic Systemic
Side effects Mild to severe side effects may occur, such as fatigue; pruritus, rash, nausea, diarrhea, and loss of appetite Side effects are small, only transient fever

Leopard Cell Advantage—iDC products combined with radiotherapy treatment

LiDCR
Treatment Combine single focused radiotherapy with intratumoral injection of autologous dendritic cells in patients with recurrent liver cancer
Indications Recurrence of liver cancer in the first, second and third phases after standard treatment
Clinical Trials Combination of single focused radiotherapy and intratumoral injection of autologous dendritic cells in the first/second phase of immunotherapy study in patients with recurrent liver cancer Confirmation of the production process for the in vitro expansion and cultivation of laboratory capacity of immature dendritic cells from healthy people
Test case number 89-11-12 20190505R
Purpose To evaluate the effect of this combination of single focused radiotherapy and intratumoral injection of dendritic cell immunotherapy in patients with recurrent liver cancer Produce immature dendritic cells with good quality in a culture method that meets the current Good Tissue (GTP)
Clinical Trial Cooperative Hospital Taipei Veterans General Hospital Shin Kong Wu Houshi Memorial Hospital
Academic achievement
SCI Journal Article
J Immunother Volume 28, Number 2, March/April 2005 Combination of Conformal Radiotherapy and Intratumoral Injection of Adoptive Dendritic Cell Immunotherapy in Refractory Hepatoma

Recreate Vitality

Contact Now